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Summary Sera from a small sample of adult blood donors, healthy school children and patients with
lymphoma, leukaemia, non-haematologic cancer, congenital and inflammatory disorders from Ibadan, Nigeria
were screened for HTLV-I antibody by an enzyme-linked immunoabsorbent assay and confirmed by investiga-
tional Western blot. Seventy-nine of 236 positively screened samples could not be tested for confirmation.
Seropositive reactivity was observed in nine of 123 blood donors, and 3 of 46 healthy school children but
banding patterns on Western blot were often sparse. Among non-Burkitt's non Hodgkin's lymphoma patients
six of 30 were HTLV-I positive including four of four with clinical features of adult T-cell leukaemia (ATL).
Other clinical conditions had a frequency of positivity indistinguishable from healthy donors. Western blot
patterns ranged from strong with multiple bands, which were uncommon, to those with only p24 and p21
envelope positive which were frequent. Given the relative paucity of clinical ATL and the unusual Western
blot patterns the true rate of HTLV-I infection may be lower than estimated. It is possible that a cross-reactive
HTLV-I-like virus accounts for this pattern.
Human T-cell lymphotropic virus type I (HTLV-I) is
endemic in various parts of the world, including the southern
coastal areas of Japan, the West Indies and, to a lesser
degree, the southeastern region of the United States among
people of African descent (Kalyanaraman et al., 1985;
Blayney et al., 1983; Catovsky et al., 1982). In Jamaica, an
HTLV-I endemic area, between 50% and 70% of all non-
Hodgkin's lymphoma cases are HTLV-I seropositive (Blatt-
ner et al., 1983; Gibbs et al., 1987). In Trinidad/Tobago,
HTLV-I infection is restricted largely to persons of African
ancestry despite the fact that the population is equally
divided between persons of Asian and African origin suppor-
ting the concept that the virus is endemic in Africa (Bar-
tholomew et al., 1985). This hypothesis was supported by our
previous case report of a Nigerian with classical adult T-cell
leukaemia/lymphoma (Williams et al., 1984) and recent
population surveys of HTLV-I in various locales of Africa
(Fleming et al., 1982; Saxinger et al., 1984; Fleming et al.,
1986; Williams et al., 1987). While the validity of the early
HTLV-I serology in Africa has been questioned (Weiss et al.,
1986) especially because of the remarkable discrepancy
between the enzyme-linked screening and confirmatory assays
when compared with the more sensitive Western immunoblot
assay (Constantine et al., 1988; CDC, MMWR, 1988), recent
advances in technology have significantly improved the
accuracy of HTLV diagnosis.
The current study evaluated HTLV in healthy subjects and
patients with various lymphoreticular and haematologic
disorders as well as other non-haematological neoplasms
from Ibadan, Nigeria. Other patients studied included
patients with chronic non-neoplastic disorders, including
infections, autoimmune and heredity disorders requiring mul-
tiple transfusions.
Methods
All patients attending the hematooncology service at the
University College Hospital, Ibadan over a 15 month period
were recruited. Eligible disease included non-Hodgkin's,
Hodgkin's, and Burkitt lymphoma (BL), acute and chronic
lymphocytic leukaemia as well as various hematologic
disorders including disorders requiring poly transfusion. One
hundred and twenty-three adult blood donors were recruited
from the hospital blood bank. Blood was also obtained from
46 Elementary School children resident in a socio-econ-
omically deprived area of the city. Aliquots of 1-2 ml of sera
from the blood samples were placed in polystyrene shipment
tubes and stored for 1-6 months at - 20'C prior to ship-
ment in dry ice to the Laboratory of Tumor Cell Biology of
the National Cancer Institute, Bethesda, MD, where they
were screened for HTLV-I antibodies by a whole virus
enzyme-linked immunoassay (ELISA) (Saxinger & Gallo,
1983). Confirmatory Western blot testing was performed
using an investigational Western blot assay incorporating the
recombinant transmembrane gene product p2le into stan-
dard whole virus (Biotech, Inc) (Liliehoj et al., 1989). The
seropositivity rates were computed as the product of the
probabilities of positive outcome of the two tests. The 95%
confidence intervals were computed from these characteristics
using a standard statistical methodology.
Several patterns of Western blot results were identified: a
multi-band pattern including strong reactivity with the gag
antigen p24 and either with the external envelope gp46 and/
or a recombinant p2le transmembrane portion of the
envelope; an oligo banding pattern, usually p24 and gp2le;
an 'indeterminate pattern' where single or multiple bands
including both gag and envelope reactivity; and a negative
pattern where all bands were absent. Positives included all
samples with at least a gag and envelope reactivity. Indeter-
minants were classified as negative. These criteria of
definition of reactivity pattern are similar to those suggested
recently (CDC, MMWR, 1988) for confirming blood bank
screen positive samples.
In selected cases mononuclear cells recovered from blood,
ascitic fluid or teased form tissue biopsy samples were
phenotyped with a panel of monoclonal antibodies, including
OKT-llA (anti-E-rosette receptor), WT-l (anti-T), OKT-3,
OKT-4, and OKT-8 using indirect immunofluorescence.
Adult T-cell leukaemia/lymphoma (ATL) was diagnosed in
this study primarily on clinical grounds depending on the
presence of, at least, any two of the following characteristic
clinical features: hypercalcaemia occurring at any time in the
course of the disease, cutaneous involvement, osteolytic
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lesion and leukaemic peripheral and marrow blood picture.
Demonstration of mature and/or helper T-cell phenotype was
considered as additional supportive evidence. Similar criteria
were applied in the characterisation of ATL in Jamaica
(Gibbs et al., 1987).
Results
In Table I are summarised the results of the serosurvey of
various disease states, and the healthy school children and
normal donors. There were a total of 30 paitents with non-
Hodgkin's, non-Burkitt's lymphoma (NH/NBL) of whom six
were confirmed HTLV-I seropositive. Of these cases four had
features ofATL and all four were HTLV-I positive. With the
exception of one case with borderline hypercalcaemia, none
of the remaining 26 cases had features of ATL. Thus, 100%
of ATL cases in this survey were HTLV-I seropositive.
Otherwise, seropositivity rates among patients with non-ATL
NH/NBL, BL, Hodgkin's disease, variants of leukaemia and
other haemopoietic malignancies, non-haemopoietic malig-
nancies and chronic non-neoplastic disorders did not differ
from those among healthy blood donors (mean age: 23.9
years) or school children (mean age: 8.9 years).
Among ATL cases atypical large mononuclear cells were
observed in the bone marrow but not peripheral blood
smears of cases K0250, K0319, and K4950 (Table II). Histo-
logic features were those of aggressive lymphoma with 'biz-
zare' (K0319), plasmacytoid (K0250), centroblastic (K4950)
or 'high grade' (K1282) cell types.
In Table II are summarised the clinical features of the four
ATL cases and two positive NB/NBL. There were two male
and two female ATL cases, the youngest being 12 years old
and the oldest 47. One of four had skin involvement, three of
three bone marrow involvement and three of four with lytic
bone lesions. Two of three tested had hypercalcaemia and
two of two tested had T-cell phenotype. Two of three had
bulky extranodal involvement. The clinical course of disease
was rapid with death usually occurring within weeks of
admission. The two positive NH/NBL had not been ade-
quately investigated and did not manifest enough clinical
features for the establishment of a diagnosis of ATL. The
cases of Burkitt's lymphoma presented with typical clinical
and laboratory features of the disease including median age
of 5.5 years, small non-cleaved pyroninophilic lymphoid cells
(7/7), jaw tumours (5/7) and mesenteric abdominal masses
(4/7). The seven seropositive cases consisted of five of 40
(12.5%) consecutive previously untreated BL patients, and
two of seven (28.6%) patients studied in remision (BL-R).
Summarised in Table III are the Western blot patterns for
the cases and normal controls. Four of five positives were
females and they represent the only cases where both p2le
(transmembrane envelope) and gp46 external envelope re-
activity was present. In general the remaining cases had
weaker reactivity with an oligo banding pattern present.
Discussion
The case series reported here confirms previous reports of a
strong correlation of HTLV-I to non-Hodgkin's lymphoma
patients with features of adult T-cell leukaemia as originally
TableI Results ofHTLV-I testing in normaldonorandpatientswithneoplastic andnon-neoplastic diseases attheUniversity College Hospital,
Ibadan, Nigeria
No. with ELISA ODbratio>cutoff± WB confirmed 95%
No. with ELISA % Confidence
OD ratio< Total no. Sero- interval
cutoff NEG IND POS ND studied positivity/ %
Lymphoma
ATL 0 0 0 4 0 4 100 -
Non-ATL NH/NBL 6 9 2 2 7 26 11.5 0-42.2
BL 25 8 6 7 1 47 15.4 0-35.4
HD 7 3 3 0 0 13 0 -
Cancers
Acute leukaemia 12 7 0 3 4 26 15.9 0-48.7
CLL 13 4 1 2 1 21 10.9 0-39.6
CML 3 4 1 0 1 9 0 -
Others I 1 6 3 2c 6 28 11.3 0-41.1
Non-neoplastic 11 11 1 3 7 33 13.4 0-50.9
chronic
diseases
Normal subjects
Blood donors 42 29 16 9 27 123 11.0 0-24.8
School children 14 3 1 3 25 46 21.2 0-57.9
Total no. studied 144 84 34 39 79 380 14.3 6.6-24.4
NEG: negative. IND: indeterminate. POS: positive. ND: not done. WB: Western blot. aSee Methods for description ofderivation. bOptical
density. CI/3 cases ofhepatoma and 1/1 case ofWilm's tumour.
Table II Clinical and laboratory features ofpatients diagnosed clinically to have ATL or who have HTLV-I
seropositive malignant lymphoma (excluding Burkitt's lymphoma)
T-cell
Age/ Leuk- Other Serum pheno- Diagn- HTLV-I
ID No. sex aemia Skin BM Bone site Ca+ + type osis WB
K0250 47/M No No Yes Jaw Mouth 1O.Oa ND ATL POS
Floor
K0319 12/M No No Yes ND Liver 12.8a CD4 + ATL POS
K1282 39/F No Yes ND Skull No ND ER +; ATL POS
CD2 +
K4950 22/F No No Yes Ilium ND 9.3 ND ATL POS
K1299 15/F No No Yes ND ND 9.8a ND NHL POS
K5013 52/F No No ND No No ND ND NHL POS
WB: Western blot. ND: not done or not examined. BM: bone marrow. ER: sheep red blood cell receptor.
aElevated serum calcium level (in mgdl
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Table III Western blot reactivity in cases and controls
ID No. Age/sex DX P19 P24 P15 P21e P26 P28 P32 P42 GP46 P53
K0250 47/M ATL 1 - 1 -
K0319 12/M ATL - 1 - 1 1 - - -
K1282 39/F ATL 3 3 1 3 - 2 1 1 1 1
K4950 22/F ATL - 1 1 1 - - - - -
K1299 15/F NHL 1 - 1 I
K5013 52/F NHL - 2 - 1 - - - - -
K0265 12/M BL 2 2 - 3 - 2 2 - 3 3
K0256 14/F BL-R 3 3 1 ND 3 3 2 2 3 2
K0260 4/F BL - 1 - 1 - 1 - 1 - -
K0270 12/F BL-R - 1 - 1 - I
K0288 8/M BL 2 2 - 1 - 1 1
K1269 5/M BL - 1 - 1 - - I
K5017 16/M BL 1 1 1 1 - - -
K1270 33/F CLL 3 3 - 3 - 1 1 1 1 -
K1279 15/F ALL - 1 - 2 - - - 1 - -
K1217 60/F AML 3 3 3 3 1 3 3 2 3 3
K1257 13/F AML - 1 - 2 - - - - - -
K0308 26/M ABD 1 1 1 - - - I -
K1232 24/M ABD 1 - 1 - - - - -
K1239 22/M ABD 1 2 - - - 1 -
K1240 22/M ABD 1 - 1 - 1 - 1 -
K1356 26/M ABD 1 1 1 1 - - - - -
K4944 28/M ABD 1 1 1 - - - - -
K4945 30/M ABD - 1 1 - - - - -
K4962 22/M ABD 3 1 1 1 1 2 1 - -
K4971 24/M ABD 2 1 - I - - - - -
K5041 8/Fe NSC 1 1 2
K5042 8/Fa NSC 1 1 - 1 - -
K5051 9/M NSC 2 2 - - - - -
ABD: adult blood donor; NSC: normal school children. BL-R: Burkitt's lymphoma studied in remission. Other
abbreviations are explained in text. aPresumed to be twin sisters.
described in Japan and subsequently reported in residents of
Jamaica, Trinidad and other locales in Caribbean as well as
among West Indian immigrants to the United Kingdom and
the US. The cases reported here while few in number
confirm, along with our previous report of ATL in Ibadan,
that HTLV-I and its associated lymphoma are documentable
in Nigeria.
Although nine of our seropositive patients had typical
B-cell lymphoproliferative disorders (two of 21 CLL, and
seven of 47 Burkitt's lymphoma patients), it is likely that
these represent coincidental infection since rates of positivity
were no different from those in blood donors. ATL con-
stituted four of the 30 NH/NBL cases (13.3%) in this
population, in sharp contrast to the 50 to 60% rate observed
in the endemic areas of Jamaica and Japan. The low propor-
tion of ATL among our NH/NBL cases could be due either
to an increase of non-ATL NH/NBL or to a reduced
prevalence of ATL in the study population. A similar situa-
tion has been reported by Delaporte et al. (1988, 1989) in
other parts of Africa and could occur for several reasons.
Under ascertainment may result from the death of a patient
before coming to medical attention, a factor compounded by
the poor health services of the study area. Reduced recogni-
tion of ATL as a clinical entity could also be a factor. The
clinical features of ATL in Nigeria differed from those des-
cribed in other endemic areas. For example, the cases from
Ibadan had a bulkiness of lymph node (Williams et al., 1987)
and extranodal involvement that appears more pronounced
than those of cases from Japan and Jamaica, but similar to
the observations of Fleming et al. (1986) in another part of
Nigeria. It is also possible that HTLV-I predisposes to high
mortality early in life resulting in a loss to death of persons
who otherwise would have developed ATL as adults, possibly
through the causation of immunodeficiency as described in
the HTLV-I associated paediatric syndrome of infective der-
matitis (LeGrenade et al., 1990).
Much of the controversy surrounding the prevalence of
HTLV-I infection in Africa results from inadequancies of
early assays for detecting true seropositivity. The recent
availability of second generation assays such as the p2le
enhanced HTLV-I Western blot provide a more reliable
serologic marker for detecting HTLV-I infection. For the
purpose of this study, we have interpreted the requirement
for seropositivity as minimally involving reactivity to p24 and
p2le, or with p24 and gp46. As shown in Table III we
observed that the combination ofp24 and p2le is more likely
to be present than in p24 and gp46. This lack of sensitivity
for detecting gp46 has been previously reported and likely
reflects the relative paucity of gp46 antigen in whole virus
Western blot transfers (Lilienhoj et al.,1989). Furthermore,
changing criteria for seropositivity and small numbers of
tests in previous Nigerian surveys (e.g. Williams et al., 1987)
have added to instability of estimates of true seroprevalence.
Compared to serologic surveys from Jamaica, employing
identical methods of Western blot confirmation, the patterns
of seroreactivity in the current study differed. Specifically the
number and intensity of bands in samples in this study is
weaker than those observed in the known HTLV-I endemic
area of Jamaica. Furthermore, p19 bands were absent in a
significant portion of samples, including 50% and 58.8%
respectively of normal blood donors and patients whose
Western blots profiles otherwise satisfied the criteria of
seropositivity. This circumstance is reminiscent of our
previous reports from Panama where ATL is infrequent com-
pared to expected, based on background HTLV sero-
prevalence (Lairmore et al., 1990; Reeves et al., 1990). This
paradox was recently explained by studies which demon-
strated the frequent occurrence of HTLV-II in the
Panamanian population (Lairmore et al., 1990) where, as
pointed out by Wiktor et al. (1990), a hallmark of HTLV-II
reactivity is a diminished or absent p19 band compared to
p24. While some cases in this study had absent p19 reactivity
reminiscent of the findings in Panama and among int-
ravenous drug users, this reactivity is unlikely to result from
HTLV-II since this pattern was only seen in those with the
weakest banding patterns. Thus, the finding in the current
study in Nigeria of a lower than expected occurrence of ATL
and high rate of Western blot reactivity but with aberrant
profile (i.e. weak reactivity and sparse banding) suggests the
possibility that a mixutre of true HTLV-I positivity and cross
reactivity with a related virus may explain this paradox. An
HTLV-II-like virus which has been recently reported in West786 C.K.O. WILLIAMS et al.
Africa could be a candidate (Delaporte et al., 1991). Alterna-
tively, sera from Africa have been notoriously difficult to
reliably test because of high rates of positivity (Biggar et al.,
1985). Conditions of specimen collection, storage and trans-
portation are unlikely to have contributed significantly to
these difficulties. Ultimately, however, in this population
there is a need to evaluate virus type by culture and PCR to
determine the true nature of this reactivity.
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